NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Seaport Therapeutics SPTX

Seaport Therapeutics listed on Nasdaq on 1 May 2026 and is not in the S&P 500. It is worth $981 million. 11 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 4 other officers are on file. At 30 Jun 2026, Arch Venture Management was its largest institutional holder, with 11.8% of the company.

CEO
Daphne Zohar
Listed
1 May 2026 on Nasdaq, IPO filings and terms
Headquarters
Boston, MA
Market cap
$981M
19 Nov 2026 close
Revenue
-
No annual report yet

Board and leadership

Board and officers

1 person here also holds roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (11)
Daphne ZoharChief Executive OfficerChief Executive Officer
Atlantic (Lux) S.a R.L. GeneralDirectorDirector
Atlantic GenPar (Lux) SCSp GeneralDirectorDirector
James HealyDirectorDirector
Robert J. HombachDirectorDirector
Sharon MatesDirectorDirector
Steven M. PaulDirectorDirector
Sandra E. PetersonDirectorAlso at MicrosoftDirector
Jason PittsDirectorDirector
Denice TorresDirectorDirector
David E. WheadonDirectorDirector
Officers (4)
Lauren WhiteChief Financial OfficerLast filed 4 May 2026Chief Financial Officer
Michael Cunyuan ChenChief Scientific OfficerLast filed 4 May 2026Chief Scientific Officer
Lana GladsteinGeneral CounselLast filed 4 May 2026General Counsel
Antony LoebelChief Medical OfficerLast filed 4 May 2026Chief Medical Officer

Owners and trading

Largest institutional holders

Each fund group's share of Seaport Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Arch Venture Management11.8%
  • General Atlantic11.4%
  • Sofinnova Investments6.7%
  • Goldman Sachs4.1%
  • Trv GP Vi3.9%

These five hold 37.7% of Seaport Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $335,120 in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
3 Nov 2026BuyDenice TorresDirectorDirectorBuy5,000$99K
22 Jun 2026BuyRobert J. HombachDirectorDirectorBuy13,000$236K

Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years.